Archive: September 2018

Update on Managing Brain Metastases in Breast Cancer

Nancy U. Lin, MD 

H&O  How common are brain metastases in breast cancer? NL  Among women with metastatic breast cancer, up to 50% of those with human epidermal growth factor […]

Diagnosis and Management of Dysfibrinogenemia

Susan E. Shapiro, MD, PhD, MRCP, FRCPath

  H&O  What is dysfibrinogenemia, and how common is it?  SS  Dysfibrinogenemia is a qualitative functional disorder of fibrinogen. It is characterized in the laboratory by […]

Dosing Drugs in Elderly Patients With Cancer

Arti Hurria, MD

H&O  What is the rate of cancer in older patients? AH  Almost 60% of new cancer diagnoses and 70% of cancer deaths occur in patients older […]

Changing Local Therapy in Breast Cancer: Who Needs What, and When?

Batul H. Al-Zubeidy, MD, Hannah Weiss, BA, and Seema A. Khan, MD

  Abstract: The local therapy of breast cancer continues to evolve toward less surgery. Breast conservation is firmly in place, with recent trends toward decreased rates […]

Distinguishing Autoimmune Myelofibrosis from Primary Myelofibrosis

Bridget Marcellino, MD, PhD, Siraj M. El Jamal, MD, and John O. Mascarenhas, MD

  Abstract: Bone marrow fibrosis (BMF) is a histologic finding in a wide range of diseases, including malignancies, endocrine disorders, autoimmune diseases, and infections. Autoimmune myelofibrosis […]

Refining the Management of Polycythemia Vera

Ruben A. Mesa, MD

  H&O  What are the clinical characteristics of polycythemia vera? RM  Patients with polycythemia vera classically present with erythrocytosis, and they can also have thrombocytosis and/or […]

Hem/Onc News

Devon Schuyler

Pembrolizumab Receives Regular Approval in Metastatic Nonsquamous NSCLC On August 20, the US Food and Drug Administration (FDA) granted regular approval to pembrolizumab (Keytruda, Merck) for […]

Back to Archive